---
title: "Sino Biopharm’s Culmerciclib Shows Promise in Resistant Breast Cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288338622.md"
description: "Sino Biopharmaceutical reported promising Phase II data for culmerciclib, an oral CDK2/4/6 inhibitor, in treating resistant breast cancer. The drug showed a 32.4% objective response rate and manageable safety profile when combined with fulvestrant. These results support its regulatory approval in China and potential to address resistance to existing therapies. With a fully enrolled Phase III trial underway, culmerciclib aims to strengthen Sino Biopharm's oncology portfolio. Analysts maintain a 'Buy' rating on the stock."
datetime: "2026-06-01T23:46:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288338622.md)
  - [en](https://longbridge.com/en/news/288338622.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288338622.md)
---

# Sino Biopharm’s Culmerciclib Shows Promise in Resistant Breast Cancer

Sino Biopharmaceutical ( (HK:1177) ) just unveiled an announcement.

Sino Biopharmaceutical reported Phase II data for its oral CDK2/4/6 inhibitor culmerciclib, combined with fulvestrant, in hormone receptor-positive, HER2-negative advanced breast cancer patients who had progressed on prior CDK4/6 inhibitor and endocrine therapy. The regimen achieved a confirmed objective response rate of 32.4%, high disease control and clinical benefit rates, and sustained progression-free survival signals, while maintaining a manageable safety profile with low rates of severe neutropenia.

The results, presented at the 2026 ASCO Annual Meeting, reinforce culmerciclib’s potential to address resistance to existing CDK4/6 therapies and support its recent regulatory approvals in China for use with fulvestrant in both pretreated and first-line settings. With an ongoing Phase III adjuvant trial now fully enrolled, the drug could further strengthen Sino Biopharmaceutical’s oncology portfolio and competitive position in the growing market for targeted breast cancer treatments.

The most recent analyst rating on (HK:1177) stock is a Buy  
with a HK$6.50 price target.  
To see the full list of analyst forecasts on Sino Biopharmaceutical stock,  
see the HK:1177 Stock Forecast page.

**More about Sino Biopharmaceutical**

Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical group focused on innovative drugs, with a strong presence in oncology and other therapeutic areas in China. Its subsidiary Chia Tai Tianqing Pharmaceutical Group Co. Ltd. develops culmerciclib, the world’s first oral CDK2/4/6 triple inhibitor, targeting hormone receptor-positive, HER2-negative advanced breast cancer.

**YTD Price Performance:** -19.26%

**Average Trading Volume:** 76,812,804

**Technical Sentiment Signal:** Hold

**Current Market Cap:** HK$89.17B

Learn more about 1177 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)

## Related News & Research

- [Sino Biopharmaceutical Unveils HK$2 Billion Share Purchase Plan to Support Stock and Shareholders](https://longbridge.com/en/news/289702409.md)
- [Sino Biopharm Advances First-in-Class CCR8 Antibody Into Phase III Gastric Cancer Trial](https://longbridge.com/en/news/285458913.md)
- [09:30 ETLung Cancer Research Foundation Announces Request for Proposals Open for ALK-Positive Lung Cancer Research Grant](https://longbridge.com/en/news/289198209.md)
- [ADA26: Oral PCSK9 inhibitor enlicitide delivers robust LDL-C lowering](https://longbridge.com/en/news/289219859.md)
- [Sino Biopharm Showcases Promising Obesity Antibody Data and Expands Weight-Loss Pipeline](https://longbridge.com/en/news/286328735.md)